Novartis | NOVN - Trade Creditors


Novartis reported $4.32B in Trade Creditors for its fiscal quarter ending in March of 2026.





Trade Creditors Change Date
AbbVie USD 3.59B 28.65B Dec/2025
Alcon AG USD 919M 7M Mar/2026
Almirall EUR 258.05M 58.66M Dec/2025
Amgen USD 19.52B 1.37B Mar/2026
AstraZeneca USD 22.51B 2.78B Mar/2026
Autolus Therapeutics Ltd USD 1.87M 1.21M Mar/2026
Bayer EUR 6.59B 496M Mar/2026
Biogen USD 358.5M 73.5M Mar/2026
Bristol-Myers Squibb USD 4.23B 659M Mar/2026
Eli Lilly USD 5.03B 350M Mar/2026
Fresenius EUR 1.65B 564M Dec/2025
Fresenius Medical Care EUR 890.43M 54.88M Mar/2026
Genmab DKK 6M 2M Sep/2025
Gilead Sciences USD 645M 70M Mar/2026
GlaxoSmithKline GBP 14.34B 1.05B Mar/2026
GRIFOLS EUR 841M 37.68M Dec/2025
Hikma Pharmaceutical USD 715M 104M Dec/2025
J&J USD 10.46B 1.53B Mar/2026
Lakefront Biotherapeutics EUR 95.77M 8.88M Mar/2026
Lonza CHF 471M 3M Dec/2024
Merck EUR 2.13B 19M Mar/2026
Merck USD 3.86B 541M Mar/2026
Novartis USD 4.32B 134M Mar/2026
Novartis USD 4.46B 99M Dec/2025
Novo Nordisk DKK 14.8B 4.96B Mar/2026
Orion EUR 150.3M 26.8M Mar/2026
Pfizer USD 4.51B 734M Mar/2026
Philips EUR 1.99B 63M Mar/2026
Recordati EUR 306.9M 38.29M Mar/2026
Regeneron Pharmaceuticals USD 1.03B 4.81B Mar/2026
Roche Holding CHF 5.78B 1.27B Dec/2025
Sanofi EUR 22.71B 219M Mar/2026
UCB EUR 4.04B 755M Dec/2025